Company Profile

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Companyâ€™s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.

Employees

293

Sector

Advanced Medical Equipment & Technology

More about the company

End-of-day quote Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		-.--%	-

13/12/23	Haemonetics Completes $255 Million Acquisition of OpSens	MT
12/12/23	OpSens Brief: NYSE's Haemonetics Completed Acquisition	MT

13/12/23	Haemonetics Completes $255 Million Acquisition of OpSens	MT
12/12/23	OpSens Brief: NYSE's Haemonetics Completed Acquisition	MT
12/12/23	Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) for approximately CAD 330 million.	CI
08/12/23	OpSens Receives Final Order For Its Acquisition By NYSE's Haemonetics	MT
08/12/23	OpSens Brief: Says Received Final Order For Its Acquisition By NYSE's Haemonetics	MT
02/12/23	Opsens Shareholders Approve Arrangement With Haemonetics	MT
02/12/23	Opsens Inc. - Shareholder/Analyst Call
28/11/23	OpSens Brief: In connection with prior announced acquisition by Haemonetics Obtained Regulatory Clearance of Arrangement in the US and Canada; Regulatory Approvals Condition Satisfied	MT
23/11/23	Opsens Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	CI
23/11/23	OpSens Fiscal Q4 Loss Narrows as Sales Rise 57% Ahead of Acquisition by Haemonetics	MT
22/11/23	Opsens Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	CI
14/11/23	OpSens Brief: ISS Recommends Shareholders Vote For Opsens Inc. Plan of Arrangement with NYSE's Haemonetics	MT
12/10/23	Barrington Research's Initial Take on Haemonetics' Acquisition of OpSens	MT

26/11/22	Opsens Reiterated at Buy at Stifel GMP Following Management Meetings; Price Target Kept at C$3.75	MT
19/11/22	Opsens Maintained at Buy at Stifel GMP Ahead of Fiscal Q4 Results; Price Target Maintained at C$3.75	MT
30/09/22	Opsens Kept at Buy at Stifel GMP Following FDA Approval for SavvyWire; Price Target Raised to C$3.75	MT
27/09/22	Opsens Buy Rating Reiterated at Stifel GMP as SavvyWire Receives First US Use; Price Target Kept at C$3.35	MT
25/11/21	Opsens Upgraded to Strong Buy at Raymond James	MT

12/12/23	HAEMONETICS COMPLETES ACQUISITION OF OPSENS	AQ
08/12/23	OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS	AQ
02/12/23	OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS	AQ
28/11/23	OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED	AQ
23/11/23	Opsens : Management’s Discussion & analysis for the year 2023	PU

Opsens Inc. Stock Toronto S.E.

Stocks

CA6838231083

Advanced Medical Equipment & Technology

Latest news : Opsens Inc.

Analysts' recommendations : Opsens Inc.

Press Releases : Opsens Inc.

Other Advanced Medical Equipment & Technology

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OPSENS INC.	-.--%	-.--%	-	-	250M
THERMO FISHER SCIENTIFIC, INC.	+1.10%	-0.65%	+27.19%	+19.34%	225B
DANAHER CORPORATION	-0.19%	-3.62%	+5.31%	-19.41%	141B
INTUITIVE SURGICAL, INC.	+2.41%	+0.67%	-17.91%	+22.42%	130B
BOSTON SCIENTIFIC CORPORATION	-0.28%	-10.08%	-58.15%	-19.54%	62.29B
SIEMENS HEALTHINEERS AG	-0.49%	-1.97%	-19.72%	-15.81%	49.39B
EDWARDS LIFESCIENCES CORPORATION	-2.77%	-6.15%	+8.77%	+14.99%	48.63B
AGILENT TECHNOLOGIES, INC.	+2.66%	-2.61%	+19.22%	+30.28%	41.42B
WATERS CORPORATION	+1.67%	-0.25%	+38.24%	+56.84%	40.12B
RESMED, INC.	-0.60%	-4.41%	-19.20%	+46.52%	31.23B
Average	+0.35%	-3.42%	-1.81%	+15.07%	85.52B
Weighted average by Cap.	+0.67%	-2.50%	+2.73%	+10.75%